Abstract:Cancer affects millions of individuals worldwide. Thus, there is an increased need for the development of novel effective therapeutic approaches. Tumorigenesis is often coupled with immunosuppression which defeats the anticancer immune defense mechanisms activated by the host. Novel anticancer therapies based on the use of immune checkpoint inhibitors (ICIs) are very promising against both solid and hematological tumors, although still exhibiting heterogeneous efficacy, as well as tolerability. Such a differential response seems to derive from individual diversity, including the gut microbiota (GM) composition of specific patients. Experimental evidence supports the key role played by the GM in the activation of the immune system response against malignancies. This observation suggests to aim for patient‑tailored complementary therapies able to modulate the GM, enabling the selective enrichment in microbial species, which can improve the positive outcome of ICI‑based immunotherapy. Moreover, the research of GM‑derived predictive biomarkers may help to identify the selected cancer population, which can benefit from ICI‑based therapy, without the occurrence of adverse reactions and/or cancer relapse. The present review summarizes the landmark studies published to date, which have contributed to uncovering the tight link existing between GM composition, cancer development and the host immune system. Bridging this triangle of interactions may ultimately guide towards the identification of novel biomarkers, as well as integrated and patient‑tailored anticancer approaches with greater efficacy.

From Interconnection between Genes and Microenvironment to Novel Immunotherapeutic Approaches in Upper Gastro-Intestinal Cancers—A Multidisciplinary Perspective

Emerging Therapeutic Targets and Future Directions in Advanced Gastric Cancer: A Comprehensive Review

Gastric Cancer, Immunotherapy, and Nutrition: The Role of Microbiota

The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey

Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer

Revolutionizing gastric cancer treatment: The potential of immunotherapy

Current developments in gastric cancer: from molecular profiling to treatment strategy

The gut microbiome and efficacy of cancer immunotherapy

Comparing immunotherapies to other frequently used treatments of gastric cancer

Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer

Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers

Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications

Immunotherapy of Gastric Cancer: Past, Future Perspective and Challenges

Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies

From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer

Synergistic Strategies for Gastrointestinal Cancer Care: Unveiling the Benefits of Immunonutrition and Microbiota Modulation

Immunotherapy and combined treatment in gastric cancer

Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review)

A rationale multidisciplinary approach for treatment of esophageal and gastroesophageal junction cancer: Accurate review of management and perspectives

Theranostic Approaches for Gastric Cancer: An Overview of In Vitro and In Vivo Investigations